Home›Trial›NCT04883905
NCT04883905RECRUITING

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Study Summary

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Conditions
Acute Hepatic Porphyria
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
ALNY
Alnylam Pharmaceuticals
RNAi Therapeutics
F27/100
Study Details
Enrollment150 participants
Primary Completion—
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219224+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 150 participants
Sponsor Catalyst Profile

Alnylam Pharmaceuticals (ALNY) is the sponsoring company for this trial. BiotechSign currently grades this company F (27/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ALNY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.